RxDoctor Payments Data

Corrine Renne, DPM

Foot Surgery · Franklin Square, NYNPI 1740456169

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (52.9%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 21.1%. Reporting peaked in 2022 at $7,122 and has fallen 90.2% since, to $697 in 2025. Among foot surgery clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$19,709in general payments, 2019–2025

Across 142 payments — averaging $138.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medimetriks Pharmaceuticals, Inc.$4K
  • Zimmer Biomet$2K
  • Abbott$2K
  • Anika Therapeutics, Inc.$1K
  • Arthrosurface Incorporated$1K
  • Smith+Nephew$1K
  • plus $8K from 32 others

What the payments were for

  • Consulting fees$4,22421%
  • Travel & lodging$5,05126%
  • Food & beverage$10,43553%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,709 in reported general payments places this provider in the 95th percentile of 294 foot surgery providers in New York.

See all foot surgery providers in New York

Medicare billing

Part B allowed, 2024
$140,817
Medicare patients
309
Services billed
1,372

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Neo-SynalarNeomycin Sulfate/Fluocinolone48$45,097
JubliaEfinaconazole31$33,600
Ketoconazole66$21,365
Clindamycin Phosphate75$5,502
Tavaborole19$5,251
ClindacinClindamycin Phosphate13$4,697
Fluocinonide18$1,059
Clotrimazole11$552
Ciclopirox14$237

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Medimetriks Pharmaceuticals, Inc.Neo-Synalar$4,149$45,09748 claims
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$46$33,60031 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 294 foot surgery providers in New York.

Other foot surgery in Franklin Square

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →